3-ethyl-5-(1,4,5,6-tetrahydropyrimidin-6-yl)-1,2,4-oxadiazole,hydrochloride

CDD0102 HCl is a selective and potent M1 muscarinic receptor agonist for the treatment of Alzheimer's disease.

In cell lines expressing M1 receptors, CDD0102 (CDD-0102) is an efficacious muscarinic agonist. CDD0102 exhibits much lower activity at M3 and M5 receptors[1].

Following i.p. injections, CDD0102 (CDD-0102) crosses the blood-brain barrier (BBB) in a dose-dependent manner. The LD50 of CDD0102 is 190 mg/kg in toxicological studies after i.p. injections and greater than 1,000 mg/kg following oral administration. In follow-up studies, CDD0102 fully reverses memory deficits associated with IgG-192 saporin administration after oral administration at a dose of 10 mg/kg. No side effects are observed at this dose[1].

1. Messer WS Jr. The utility of muscarinic agonists in the treatment of Alzheimer's disease. J Mol Neurosci. 2002 Aug-Oct;19(1-2):187-93.